Equities

Create Bookmark Delete Bookmark Create Alert Delete Alert

IFR US ECM PRICINGS

 |  Robert Sherwood

Dyne Therapeutics (US, biotech) ─ $200m ABB. 24.2m shares (Primary) at $8.25 versus $8.25-$9.00 marketing and $9.57 last sale. MS, JEFF, STFL, GUGG. Separately, secured up to $275m credit facility from Hercules Capital.

Nektar Therapeutics (US, biotech) ─ $100m ABB. 4.3m shares (Primary at $23.50 versus $23.00-$23.50 marketing and $25.76 last sale. JEFF, PS. Wall cross. 

Tempus AI (US, medtech) ─ $650m 5y cvt at 0.75%, up 32.5% versus 1.25%-1.75% and 27.5%-32.5% marketing. MS, JPM. Upsized from $400m. Repaid $247.7m term loan. Capped call to $111.195, a 75% premium.

 ZScaler (US, security software) ─ $1.5bn 3y cvt at 0%, up 40% versus 0%-0.5% and 35%-40% marketing. CITI, GS, BARC, DB. Capped call to $784.85, a 150% premium.